Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3276-3283

  Robbins, Brian L ^a   Capparelli, Edmund V ^b   Chadwick, Ellen G ^c   Yogev, Ram ^c   Serchuck, Leslie ^d,m   Worrell, Carol ^d   Smith, Mary Elizabeth ^d,e   Alvero, Carmelita ^f   Fenton, Terence ^f   Heckman, Barbara ^g   Pelton, Stephen I ^h   Aldrovandi, Grace ⁱ   Borkowsky, William ^j   Rodman, John ^a   Havens, Peter L ^k,l  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^g FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^h BOSTON UNIVERSITY   (United States)

ⁱ CHILDREN S HOSPITAL LOS ANGELES   (United States)

^j New York School of Medicine   (United States)

^k MEDICAL COLLEGE OF WISCONSIN   (United States)

^l Children's Hospital of Wisconsin   (United States)

^m NONE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG SAFETY; FEMALE; FEVER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SALVAGE THERAPY; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; VIRUS LOAD;

ADOLESCENT; ANTI-HIV AGENTS; CHILD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; SAQUINAVIR; TREATMENT OUTCOME;

EID: 50949107933     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00224-08     Document Type: Article

References (40)

1. Ananworanich, J., P. Kosalaraksa, A. Hill, U. Siangphoe, A. Bergshoeff, C. Pancharoen, C. Engchanil, K. Ruxrungtham, D. Burger, and H.-N. S. Team. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. 24:874-879.
2. Back, D., S. Gibbons, and S. Khoo. 2006. An update on therapeutic drug monitoring for antiretroviral drugs. Ther. Drug Monit. 28:468-473.
3. Bergshoeff, A. S., P. L. Fraaij, J. Ndagijimana, G. Verweel, N. G. Hartwig, T. Niehues, R. De Groot, and D. M. Burger. 2005. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J. Acquir. Immune Defic. Syndr. 39:63-68.
4. Breilh, D., I. Pellegrin, A. Rouzes, K. Berthoin, F. Xuereb, H. Budzinski, M. Munck, H. J. Fleury, M. C. Saux, and J. L. Pellegrin. 2004. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 18:1305-1310.
5. Colombo, S., T. Buclin, C. Franc, N. Guignard, M. Khonkarly, P. E. Tarr, B. Rochat, J. Biollaz, A. Telenti, L. A. Decosterd, and M. Cavassini. 2006. Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures. Antivir. Ther. 11:53-62.
6. Dailly, E., V. Reliquet, F. Raffi, and P. Jolliet. 2005. A population approach to study the influence of nevirapine administration on lopinavir pharmacokinetics in HIV-1 infected patients. Eur. J. Clin. Pharmacol. 61:153-156.
7. Delaugerre, C., J. P. Teglas, J. M. Treluyer, P. Vaz, V. Jullien, F. Veber, C. Rouzioux, M. L. Chaix, and S. Blanche. 2004. Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J. Acquir. Immune Defic. Syndr. 37:1269-1275.
8. Dragsted, U. B., J. Gerstoft, C. Pedersen, B. Peters, A. Duran, N. Obel, A. Castagna, P. Cahn, N. Clumeck, J. N. Bruun, J. Benetucci, A. Hill, I. Cassetti, P. Vernazza, M. Youle, Z. Fox, J. D. Lundgren, and MaxCmin1 Trial Group. 2003. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J. Infect. Dis. 188:635-642.
9. Ellner, P. D., and H. C. Neu. 1981. The inhibitory quotient. A method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
10. Eron, J. J., J. Feinberg, H. A. Kessler, H. W. Horowitz, M. D. Witt, F. F. Carpio, D. A. Wheeler, P. Ruane, D. Mildvan, B. G. Yangco, R. Bertz, B. Bernstein, M. S. King, and E. Sun. 2004. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. J. Infect. Dis. 189:265-272.
11. Gianotti, N., L. Galli, A. Danise, H. Hasson, E. Boeri, A. Lazzarin, and A. Castagna. 2006. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment- experienced HIV-infected patients receiving lopinavir/ritonavir. J. Med. Virol. 78:1537-1541.
12. Grub, S., P. Delora, E. Ludin, F. Duff, C. V. Fletcher, R. C. Brundage, M. W. Kline, N. R. Calles, H. Schwarzwald, and K. Jorga. 2002. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 71:122-130.
13. Havens, P. L., M. Frank, B. Cuene, V. Decker, R. Kohler, A. Wolfe, and M. Yenter. 2004. Pharmacokinetics and safety of lopinavir/ritonavir doses greater than 300 mg/m2/dose in children and adolescents with HIV infection, abstr. 937. 11th Conf. Retrovir. Opportun. Infect., San Francisco, CA, 8 to 11 February 2004.
14. Hsu, A., G. R. Granneman, G. Witt, C. Locke, J. Denissen, A. Molla, J. Valdes, J. Smith, K. Erdman, N. Lyons, P. Niu, J. P. Decourt, J. B. Fourtillan, J. Girault, and J. M. Leonard. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
15. Hsu, A., J. Isaacson, S. Brun, B. Bernstein, W. Lam, R. Bertz, C. Foit, K. Rynkiewicz, B. Richards, M. King, R. Rode, D. J. Kempf, G. R. Granneman, and E. Sun. 2003. Pharmacokinetic-pharmacodynamic analysis of lopinavirritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 47:350-359.
16. Hsu, A., J. Isaacson, D. Kempf, M. King, R. Rode, W. Lam, S. Bruni, B. Bernstein, E. Sun, and G. R. Granneman. 2000. Trough concentration-EC50 relationship as a predictor of viral response for ABT-378/ritonavir (ABT-378/r) in treatment-experienced patients, abstr. 171. Abstr. 40th Intersci. Conf. Antimicrob. Agents Chemother., Toronto, Canada.
17. Jullien, V., S. Urien, D. Hirt, C. Delaugerre, E. Rey, J.-P. Teglas, P. Vaz, C. Rouzioux, M.-L. Chaix, E. Macassa, G. Firtion, G. Pons, S. Blanche, and J.-M. Treluyer. 2006. Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years. Antimicrob. Agents Chemother. 50:3548-3555.
18. Justesen, U. S., Z. Fox, C. Pedersen, P. Cahn, J. Gerstoft, N. Clumeck, M. Losso, B. Peters, N. Obel, A. Castagna, U. B. Dragsted, J. D. Lundgren, and MaxCmin Trial Group. 2007. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials. Basic Clin. Pharmacol. Toxicol. 101:339-344.
19. Justesen, U. S., and C. Pedersen. 2002. Diurnal variation of plasma protease inhibitor concentrations. AIDS 16:2487-2489.
20. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
21. Klein, C. E., Y.-L. Chiu, W. Awni, T. Zhu, R. S. Heuser, T. Doan, J. Breitenbach, J. B. Morris, S. C. Brun, and G. J. Hanna. 2007. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J. Acquir. Immune Defic. Syndr. 44:401-410.
22. Kline, M. W., R. C. Brundage, C. V. Fletcher, H. Schwarzwald, N. R. Calles, N. E. Buss, P. Snell, P. DeLora, M. Eason, K. Jorga, C. Craig, and F. Duff. 2001. Combination therapy with saquinavir soft gelatin capsules in children with human immunodeficiency virus infection. Pediatr. Infect. Dis. J. 20:666-671.
23. la Porte, C. J., J. C. Wasmuth, K. Schneider, J. K. Rockstroh, and D. M. Burger. 2003. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 17:1700-1702.
24. Maillard, A., J.-M. Chapplain, O. Tribut, D. Bentue-Ferrer, P. Tattevin, C. Arvieux, C. Michelet, and A. Ruffault. 2007. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients. J. Clin. Virol. 38:131-138.
25. Merry, C., M. G. Barry, F. Mulcahy, M. Ryan, J. Heavey, J. F. Tjia, S. E. Gibbons, A. M. Breckenridge, and D. J. Back. 1997. Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patients. AIDS 11:F29-F33.
26. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
27. Morse, G. D., L. M. Catanzaro, and E. P. Acosta. 2006. Clinical pharmacodynamics of HIV-1 protease inhibitors: use of inhibitory quotients to optimise pharmacotherapy. Lancet Infect. Dis. 6:215-225.
28. Murphy, R. L., S. Brun, C. Hicks, J. J. Eron, R. Gulick, M. King, A. C. White, Jr., C. Benson, M. Thompson, H. A. Kessler, S. Hammer, R. Bertz, A. Hsu, A. Japour, and E. Sun. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9.
29. Podzamczer, D., M. S. King, C. E. Klein, C. Flexner, C. Katlama, D. V. Havlir, S. L. Letendre, J. J. Eron, S. C. Brun, and B. Bernstein. 2007. High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response. HIV Clin. Trials 8:193-204.
30. Ramos, J. T., M. I. De Jose, J. Duenas, C. Fortuny, R. Gonzalez-Montero, M. J. Mellado, A. Mur, M. Navarro, C. Otero, I. Pocheville, M. A. Munoz-Fernandez, and E. Cabrero on behalf of the Spanish Collaborative Group on HIV Infection in Children. 2005. Safety and antiviral response at 12 months of lopinavir/ritonavir therapy in human immunodeficiency virus-1-infected children experienced with three classes of antiretrovirals. Pediatr. Infect. Dis. J. 24:867-873.
31. Resino, S., J. M. Bellon, and M. A. Munoz-Fernandez on behalf of the Spanish Group of HIV Infection. 2006. Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency. J. Antimicrob. Chemother. 57:579-582.
32. Resino, S., J. M. Bellon, J. T. Ramos, M. L. Navarro, P. Martin-Fontelos, E. Cabrero, and M. A. Munoz-Fernandez. 2004. Salvage lopinavir-ritonavir therapy in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 23:923-930.
33. Resino, S., I. Galan, A. Perez, J. T. Ramos, J. M. Bellon, P. M. Fontelos, M. I. de Jose, M. D. Gutierrez, E. Cabrero, and M. A. Munoz-Fernandez. 2005. Immunological changes after highly active antiretroviral therapy with lopinavir-ritonavir in heavily pretreated HIV-infected children. AIDS Res. Hum. Retrovir. 21:398-406.
34. Ribera, E., R. M. Lopez, M. Diaz, L. Pou, L. Ruiz, V. Falco, M. Crespo, C. Azuaje, I. Ruiz, I. Ocana, B. Clotet, and A. Pahissa. 2004. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 48:4256-4262.
35. Rosso, R., A. Di Biagio, C. Dentone, G. C. Gattinara, A. M. Martino, A. Vigano, M. Merlo, C. Giaquinto, O. Rampon, M. Bassetti, G. Gatti, and C. Viscoli. 2006. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. J. Antimicrob. Chemother. 57:1168-1171.
36. Saez-Llorens, X., A. Violari, C. O. Deetz, R. A. Rode, P. Gomez, E. Handelsman, S. Pelton, O. Ramilo, P. Cahn, E. Chadwick, U. Allen, S. Arpadi, M. M. Castrejon, R. S. Heuser, D. J. Kempf, R. J. Bertz, A. F. Hsu, B. Bernstein, C. L. Renz, and E. Sun. 2003. Forty-eight-week evaluation of lopinavir/ritonavir, a new protease inhibitor, in human immunodeficiency virus-infected children. Pediatr. Infect. Dis. J. 22:216-224.
37. Staszewski, S., E. Babacan, C. Stephan, A. Haberl, A. Carlebach, P. Gute, S. Klauke, Y. Hermschulte, M. Stuermer, B. Dauer, and the Frankfurt HIV Cohort. 2006. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J. Antimicrob. Chemother. 58:1024-1030.
38. Stephan, C., N. Hentig, I. Kourbeti, B. Dauer, M. Mosch, T. Lutz, S. Klauke, S. Harder, M. Kurowski, and S. Staszewski. 2004. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 18:503-508.
39. Taburet, A. M., G. Raguin, C. Le Tiec, C. Droz, A. Barrail, I. Vincent, L. Morand-Joubert, G. Chene, F. Clavel, and P. M. Girard. 2004. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin. Pharmacol. Ther. 75:310-323.
40. van der Lee, M., G. Verweel, R. de Groot, and D. Burger. 2006. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. Antivir. Ther. 11:439-445.